Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus

Lupus

Volumn 5, Issue 3, 1996, Pages 206-211

  Martini, F ^a,b   Farsi, A ^a   Gori, A M ^a   Boddi, M ^a   Fedi, S ^a   Domeneghetti, M P ^a   Passaleva, A ^a   Prisco, D ^a   Abbate, R ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Clin Medica Generale e Cardiologia   (Italy)

Author keywords

Antiphospholipid antibodies; Monocyte; Procoagulant activity; SLE

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PROCOAGULANT; THROMBOPLASTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOGENESIS;

EID: 0029949753     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500307     Document Type: Article

References (47)

1. Vermylen J, Blockmans D, Spitz B, Deckmin H. Thrombosis and immune disorders. Clin Haematol 1986; 15: 393-412.
2. Mc Neil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
3. Lechner K, Etchinger S, Jager U et al. Lupus anticoagulant and clinical correlates. In: Thrombosis an update, (ed). Scientific Press, Florence, 1992: 47-60.
4. Harris EN, Gharavi AE, Boey MH. Anticardiolipin antibodies: detection by radio-immunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4.
5. Lechner K, Pabinger-Fasching I. Lupus anticoagulant and thrombosis. A study of 25 cases and review of literature. Haemostasis 1985; 15: 254-62.
6. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Int Med 1990; 112: 682-98.
7. Long AA, Ginsberg JS, Brill-Edwards P et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemostas 1991; 66: 520-4.
8. Bick RL, Baker WF. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 1992; 6: 1287.
9. Lord RHH, Podberg WM, DiStefano R. Immunohistologic profile of cells infiltrating acutely rejecting and long-surviving rat cardiac allografts. Transplant Proc 1988; 20: 229.
10. Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Semin Hematol 1992; 29: 202.
11. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
12. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992; 34: S15-S27.
13. Schwager I, Jungi TW. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 1994; 83: 152-60.
14. Del Prete GF, De Carli M, Lammel RM et al. Th1 and Th2 T helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 1995; 86: 250-257.
15. Harris EN, Baguley E, Asherson RA, Hughes GRV. Clinical and serological features of the antiphospholid syndrome. Br J Rheumatol 1987; 26: 19.
16. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research, II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 541-7.
17. Exner TE, Rickard KA, Kronberg H. A sensitive test demonstrating lupus Anticoagulant and its behavioural patterns; Br J Haematol 1978; 40: 143-51.
18. Thiagarajan P, Pengo V, Shapiro SS. The use of diluted Russel Viper venom time for the diagnosis of Lupus Anticoagulants. Blood 1986; 68: 869-74.
19. Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the Lupus anticoagulant. Blood 1976; 48: 499-509.
20. Reber G, Roisin JP, Vogel JJ, Martinoli JL, de Moerloose P. An improved platelet neutralization procedure as confirmatory test for the presence of lupus anticoagulant. Thromb Haemost 1991, 65: 1103.
21. Reber G, Roisin JP, Miguad M, de Moerloose P. Diagnostic of lupus anticoagulant with a new APTT reagent and hexagonal phase phospholipids neutralization procedure. Vth International Symposium on Antiphospholipid antibodies. San Antonio, USA, 9-12 September 1992: P3-06 (abstract).
22. Tincani A, Meroni PL, Brucato et al. Antiphospholipid and antimitochondrial type M5 antibodies in systemic lupus erythematosus. Clin Exp Rheumatol 1985; 3: 321-6.
23. Harris EN, Gharavi AE, Patel SP, Huhes GRV. Evaluation of the anticardiolipin test: report of an International Workshop held on 4th April 1986. Clin Exp Immunol 1987; 68: 215-22.
24. Helin H, Edgington TS. Allogenic induction of the human T cell-instructed monocyte procoagulant response is rapid and is elicited by HLA-DR. J Exp Med 1983; 158: 962-75.
25. Otnaess AB, Prydz H, Bjorklid E, Berre A. Phospholipase C from bacillus cereus and its use in studies of tissue thromboplastin. Eur J Biochem 1972; 27: 238-43.
26. Zacharski LR, Rosenstein R, Phillips G. Concanavamin A inhibition of tissue factor (thromboplastin) activity. Blood 1974; 6: 783-7.
27. Gordon SG, Cross BA. A factor X-activating-cysteine protease from malignant tissue. J Clin Invest 1981; 67: 1665-71.
28. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57: 144-7.
29. Meyer O, Piette JC, Bourgeois P et al. Antiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosis (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. J Rheumatol 1987; 14: 502-6.
30. Meyer O, Cyna L, Bourgeois P, Kahn MF, Ryckewaert A. Profile and cross-reactivities of antiphospholipid antibodies in systemic lupus erythematosus and syphilis. Clin Rheumatol 1987; 6: 369-77.
31. Derksen RH, Hasselaar P, Blokzijl L, Gmeling Meyling FH, De Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364-71.
32. Weidman CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. Studies of IgG, IgM, IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988; 15: 74-9.
33. Ginsberg JS, Demers C, Brill-Edwards P et al. Acquired free protein S deficiency is associated with antiphopholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995; 98: 379-83.
34. Giusti B, Gori AM, Attanasio M, Martini F, Boddi M, Livi C, Massai G, D'Elios MM, Brunelli T, Abbate R; Lupus anticoagulant and monocyte procoagulant activity in polyabortive women. Autoimmunity 1993; 15: 299-304.
35. De Prost D, Ollivier V, Ternisien C, Chollet-Martin S. Increased monocyte procoagulant activity of lupus anticoagulant in patients with systemic lupus erythematosus. Thromb Haemost 1990; 64: 216-21.
36. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor activity in monocytes by anticardiolipin antibodies. J Immunol 1994; 153: 1328-32.
37. Bakimer R, Fishman M, Blank B et al. Induction of primary antiphospholipid syndrome with a human monoclonal anitcardiolipin antibody (H-3). J Clin Invest 1992; 89: 1508.
38. Drake TA, Wolfram R, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-95.
39. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
40. Branch DW, Rodgers GM. Induction on endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-10.
41. Rapoport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
42. Novotny WF, Brown SG, Girard TJ, Miletich JP, Broze GJ Jr. Plasma LACI antigen in patient samples; Blood 1989; 74 (Suppl. 1): (abstract 209A).
43. Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, Balsano F. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. Br Med J 1990; 300: 1099-1102.
44. Jurado M, Paramo JA, Guttierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 1992; 68: 516-20.
45. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Lobato-Mendizabal E et al. Disturbance in the tissue plasminogen activator/plasminogen activator inhibitor (tPA/PAI) system in systemic lupus erythematosus. Am J Hematol 1991; 37: 9-13.
46. Awada H, Barlowatz-Meimon G, Dougados M et al. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis. J Lab Clin Med 1988; 111: 229-36.
47. Francis RB, Neely S. Effect of the lupus anticoagulant on endothelial fibrinolytic activity in vitro. Thromb Haemost 1989; 61: 314-317.